Fig. 6From: Potential factors contributing to the poor antimicrobial efficacy of SAAP-148 in a rat wound infection modelIn vitro killing assay of SAAP-148 against MRSA in PBS, plasma, eschar or skin extract. Approximately 105 CFU/mL MRSA that was suspended in PBS or in PBS with 50% (v/v) plasma, or 50% (v/v) eschar extract, or 50% (v/v) skin extract, was exposed to 10 µL of increasing dosages (0–30 nmol) of SAAP-148 in PBS. Results are expressed as the LR versus the amount of SAAP-148 in nmol. Each value represents the mean ± SD of three independent experiments performed in duplicateBack to article page